Fidelity Disruptive Medicine ETF FMED

Medalist Rating as of | See Fidelity Investment Hub

Morningstar’s Analysis FMED

Will FMED outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Fidelity Disruptive Medicine ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FMED

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 31.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Fidelity Securities Lending Cash Central Fund

8.93 4M
Cash and Equivalents

10x Genomics Inc Ordinary Shares - Class A

4.12 2M
Healthcare

Danaher Corp

3.91 2M
Healthcare

Thermo Fisher Scientific Inc

3.63 2M
Healthcare

LifeStance Health Group Inc Ordinary Shares

3.21 2M
Healthcare

argenx SE ADR

2.93 1M
Healthcare

Revolution Medicines Inc Ordinary Shares

2.85 1M
Healthcare

Alnylam Pharmaceuticals Inc

2.85 1M
Healthcare

Cogent Biosciences Inc

2.83 1M
Healthcare

Illumina Inc

2.50 1M
Healthcare

Sponsor Center